Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency  by Lee, Diana M. et al.
Kidney International, Vol. 61 (2002), pp. 209–218
Lipoprotein particle abnormalities and the impaired lipolysis
in renal insufficiency
DIANA M. LEE, CAROLYN KNIGHT-GIBSON, OLA SAMUELSSON, PER-OLA ATTMAN,
CHI-SUN WANG, and PETAR ALAUPOVIC
Department of Obstetrics & Gynecology, University of Oklahoma Health Sciences Center, and Lipid and Lipoprotein
Laboratory, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA; Department of Nephrology,
Sahlgrenska University Hospital, Go¨teborg, Sweden; and Protein Studies Research Program, Oklahoma Medical Research
Foundation, Oklahoma City, Oklahoma USA
lipid composition of all three TG-rich lipoprotein particles andLipoprotein particle abnormalities and the impaired lipolysis
increased concentrations of Lp-A-II:B:C:D:E particles repre-in renal insufficiency
sent the main factors affecting the in vitro lipolytic rates ofBackground. Increased concentrations of very low- (VLDL)
VLDL  IDL substrate in both the CRF patients before dial-and intermediate-density (IDL) lipoproteins in chronic renal
ysis and patients on hemodialysis.failure (CRF) are thought to result from a defect(s) in degrada-
tion of plasma triglyceride (TG)-rich lipoproteins. The purpose
of this study was to identify lipoprotein abnormalities associ-
ated with the reduced lipolytic rate constant, k1, of combined Chronic renal failure (CRF) is characterized by specificVLDL and IDL substrate from renal patients and asymptom-
compositional and metabolic abnormalities of plasmaatic controls.
Methods. The VLDL  IDL were isolated from 18 predia- lipoproteins [1–6]. One of these abnormalities is the in-
lytic patients (CRF-I), 8 patients on hemodialysis (CRF-II) creased concentration of very low-density (VLDL) and
and 10 asymptomatic controls. The lipolytic rate constant (k1) intermediate-density (IDL) lipoproteins considered toof VLDL  IDL was measured by an assay using bovine milk
result from a defect in degradation rather than formationlipoprotein lipase and determination of TG before and after
of triglyceride (TG)-rich lipoproteins [6–9]. Impairedincubation by gas chromatography (GC). Neutral lipids were
measured by GC and apolipoproteins by electroimmunoassays; degradation of TG-rich lipoproteins in patients with CRF
the apolipoprotein-defined TG-rich lipoproteins including may be due either to a deficient lipolytic system [6–8,
Lp-B:C, Lp-B:C:E and Lp-A-II:B:C:D:E were determined by 10–13] and/or an inadequate substrate composition [6,immunoaffinity chromatography.
14–16]. Arnadottir et al have observed that VLDL parti-Results. The k1 values of VLDL  IDL were significantly
cles from patients on hemodialysis were lipolyzed to a(P  0.001) lower in CRF-I and CRF-II patients (0.0341 and
0.0352 min1, respectively) than controls (0.0515 min1). The lesser extent than VLDL particles from healthy controls,
levels of apolipoproteins B, C-III and E, and TG-rich Lp-B:C, and suggested that increased relative contents of choles-
Lp-B:C:E and Lp-A-II:B:C:D:E particles normalized to 100 mg
terol and phospholipids, and, in particular, increased lev-TG per VLDL  IDL were significantly higher in both groups
els of apolipoprotein (apo) C-III bound to apoB-contain-of CRF patients than in controls. All three TG-rich lipoproteins
were characterized by significantly increased percent contents ing lipoproteins may represent the main compositional
of free (FC) and esterified (CE) cholesterol and a decreased abnormalities interfering with the lipolytic degradation
percentage of TG. The k1 values of the combined CRF-I and of uremic TG-rich lipoproteins [14–16].
CRF-II patient groups showed significant negative correlations
Triglyceride-rich lipoproteins of very low and interme-(P  0.001) with FC (r  0.81) and CE (r  0.63) and a
diate densities represent a mixture of particles heteroge-positive correlation with TG (r  0.72). Among lipoprotein
particles, only Lp-A-II:B:C:D:E levels showed a significant neg- neous with respect to chemical, physical and metabolic
ative correlation with k1 values (r  0.47, P  0.03). properties [17–19]. The heterogeneous character of TG-
Conclusions. This study shows that the abnormal neutral rich lipoproteins has been attributed to the presence of
several, discrete lipoprotein families of particles charac-
terized by similar density properties but distinct quali-Key words: chronic renal failure, lipids, apolipoproteins, triglycerides,
VLDL, uremia, hemodialysis. tative apolipoprotein composition [20]. Three major
TG-rich lipoprotein families identified as lipoproteinReceived for publication June 26, 2001
(Lp) B:C, Lp-B:C:E and Lp-A-II:B:C:D:E differ fromand in revised form August 17, 2001
Accepted for publication August 27, 2001 one another not only chemically, but also with respect
to metabolic properties. It has already been shown, perti- 2002 by the International Society of Nephrology
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nent to this study, that these TG-rich lipoprotein families to a final concentration of 1 mmol/L. A freshly prepared
antioxidant, butylated hydroxytoluene, was added to adiffer in their relative affinities for lipoprotein lipase
(LPL) in that the affinity of Lp-A-II:B:C:D:E particles final concentration of 0.005% [22]. Plasma was blown
gently with a stream of argon over the surface to preventis significantly lower than those of Lp-B:C and Lp-B:C:E
particles [21]. To further explore the compositional the contact with air, and the tube was covered air-tight
with double-layered parafilm.abnormalities that may be interfering with the normal
lipolytic degradation and consequent accumulation of
Isolation of lipoproteinsTG-rich lipoproteins in renal insufficiency, we have con-
ducted a kinetic and compositional study of TG-rich The VLDL and IDL were isolated from individual
plasma samples by density gradient ultracentrifugationlipoproteins isolated from predialytic CRF patients, pa-
tients on hemodialysis and healthy control subjects. The according to a modified procedure of Lee and Downs
[23]. The surface of the quick-seal polyallomer centrifugespecific aim of this study was to determine and compare
the lipolytic rate constants, k1, and lipid, apolipoprotein tubes was purged with argon, and 17 mL of pre-chilled
NaCl solution (d  1.021 g/mL) containing 3 mmol/Land lipoprotein family profiles of TG-rich lipoproteins
(VLDL LDL, d 1.019 g/mL) between renal patients EDTA and 10 mmol/L εACA were placed to the bottom
of the tube. Plasma was then delivered to the bottom ofand healthy controls.
the tube and layered underneath the salt solution. Tubes
sealed with heat were centrifuged in a 50.2 Ti rotor at
METHODS
43,000 rpm for 21 hours at 5C. Lipoproteins floating to
The study was conducted in accordance with the ethi- the top of the tube were collected under a stream of
cal principles described by the Declaration of Helsinki argon. The density of the top-layer solution was mea-
and was approved by the Sahlgrenska University Hospi- sured to be 1.019 g/mL indicating that the samples col-
tal Ethics Committee. lected encompassed VLDL and IDL. The VLDL IDL
fractions from both patients and controls were kept un-
Subjects
der argon and used within two days of isolation.
Twenty-six adult, non-diabetic patients with CRF were
Isolation of bovine milk LPLinvestigated. There were 18 predialytic patients (CRF-I;
11 men and 7 women; mean age 50  13 years) with a Bovine milk lipoprotein lipase was first enriched from
reduced glomerular filtration rate (GFR) ranging from bovine skim milk by the affinity coflotation with added
5 to 59 mL/min/1.73 m2 body surface area (BSA; mean Intralipid, followed by acetone-ether treatment and lyo-
GFR 30.8  14.6 mL/min/1.75 m2 BSA). The second phylization [24]. On the day of experiment, the LPL was
group of 8 patients (CRF-II; 3 men and 5 women; mean isolated as described previously [25] with minor modifi-
age 61  14 years) with end-stage renal failure was cations. The lyophilized LPL-acetone-powder (40 mg)
treated with chronic hemodialysis. Ten healthy, asymp- was stirred in (4 mL) 50 mmol/L NH4OH–NH4Cl buffer,
tomatic subjects (7 men and 3 women; mean age 46  pH 8.5, containing 0.1% Triton N-101 (Sigma). The solu-
13 years) served as controls. tion was centrifuged to remove the insoluble portion.
The CRF patients were treated with antihypertensive The clear solution was applied to a heparin-Sepharose
drugs, phosphate-binding drugs and vitamins as appro- mini-column calibrated to contain 1 mL of wet gel. The
priate. Patients treated with corticosteroids, immunosup- column was washed sequentially with 4 mL of 50 mmol/L
pressive agents or lipid-lowering drugs were excluded NH4OH–NH4Cl buffered 0.3 mol/L NaCl and 4 mL of buf-
from the study. fered 0.72 mol/L NaCl and then eluted with 3 mL of buf-
The CRF-II patients were dialyzed with conventional fered 2 mol/L NaCl, pH 8.5. The activity of the isolated
low-flux hemodialysis treatment generally for four to five LPL was measured with artificial substrate p-nitrophenyl
hours three times weekly using bicarbonate and glucose acetate and monitored at 418 nm. The average enzyme
containing dialysis fluid. Low-molecular-weight heparin activity was measured to be 0.231  0.050 mol/min/mL
(LMWH) was used as anticoagulant. throughout all experiments.
Blood samples were drawn after a 12-hour overnight
Lipolysis of triglyceride-rich lipoproteinsfast into ethylenediaminetetraacetate (EDTA)-contain-
ing tubes. In CRF-II patients, blood was drawn imme- Freshly isolated VLDL IDL fractions were incubated
diately before hemodialysis treatment and administra- at 37C under argon with freshly prepared bovine milk
tion of LMWH. Protease inhibitor, ε-amino caproic acid LPL at a substrate:enzyme ratio of 50:1 (vol:vol). The
(εACA), was added to a final concentration of 10 mmol/L, substrate was adjusted to a constant TG concentration
and plasma samples were shipped from Go¨teborg to of 100 mg/dL in 50 mmol/L ammonium buffer, pH 8.5.
Oklahoma City by overnight mail. Upon arrival, the LPL Fatty acid-free bovine albumin (108 mg/mL) was in-
cluded as a fatty acid acceptor in a total volume of 5 mLinhibitor, diisopropyl fluorophosphate (DFP), was added
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of lipolytic mixture. Aliquots were taken out from the in- and R-fractions to a volume of 1 to 1.5 mL. After re-
cording final volumes, the apoB contents of U- andcubation mixture at time intervals 5, 10, 15, 30 and 60
minutes, and immediately extracted with n-heptane-iso- R-fractions were quantified by electroimmunoassay [29].
The R-fraction from the anti-apoA-II immunosorberpropanol (3:7, vol:vol) for TG analyses. A mixture con-
taining no LPL served as a 0-time point. The VLDL  contained Lp-A-II:B:C:D:E particles and the U-fraction
the remaining apoB-containing lipoprotein families. If theIDL fractions from patients and controls were incubated
simultaneously with the same freshly isolated LPL prep- U-fraction reacted positively with antibodies to apoA-II,
it was rechromatographed on the anti-apoA-II immuno-aration.
The TG levels in VLDL  IDL fractions before and sorber until free of apoA-II. The R-fraction from the anti-
apoC-III immunosorber contained Lp-B:C, Lp-B:C:E,after incubation with LPL at various time intervals were
determined in duplicate samples by gas chromatography and Lp-A-II:B:C:D:E particles, while the U-fraction con-
tained cholesterol-rich Lp-B and Lp-B:E particles. If this(GC) according to the method of Kuksis et al [26].
The pseudo-first order rate (k1) of lipolysis of VLDL latter fraction still reacted positively with anti-apoC-III
serum, it was rechromatographed until free of apoC-IDL fractions was calculated from the decreasing TG
concentrations at various time intervals using a computer III. The R-fraction from the anti-apoE immunosorber
consisted of Lp-B:C:E, Lp-A-II:B:C:D:E and a negligiblesoftware, Graphic Pad, with the exponential regression
equation. The TG value at 0-time (1 mg/mL) was taken amount of Lp-B:E; the U-fraction contained Lp-B and
Lp-B:C particles. If still reacting positively with anti-as 100%.
apoE serum, the U-fraction was rechromatographed un-
Isolation and measurement of lipoprotein families til free of apoE-containing lipoproteins. The VLDL 
IDL fractions as well as R- and U-fractions from allThe TG-rich lipoprotein families Lp-B:C, Lp-B:C:E
and Lp-A-II:B:C:D:E were isolated by immunoaffinity three immunosorbers were analyzed for apoB contents.
The levels of Lp-B:C particles were calculated by sub-chromatography of VLDL  IDL fractions on anti-
apoA-II, anti-apoC-III and anti-apoE immunosorbers tracting apoB values of apoE-R fraction from those of
apoC-III-R fraction. The concentrations of Lp-B:C:Eand their concentrations were expressed in terms of
apoB contents. Anti-apoA-II, anti-apoC-III and anti- particles were determined by subtracting apoB levels of
apoA-II-R faction from corresponding apoB levels ofapoE immunosorbers were prepared by coupling poly-
clonal affinity-purified antisera to Affi-Gel 10 as pre- apoE-R fraction. The Lp-A-II:B:C:D:E concentrations
were expressed as apoB levels of apoA-II-R fraction. Theviously described [21, 27, 28]. Aliquots of VLDL  IDL
fractions (0.15 - 0.3 mL) were applied to immunosorbers acceptable recoveries of apoB from R- and U-fractions
ranged between 75 and 90%; all values were adjustedand incubated overnight at room temperature. The elu-
tion of retained and unretained fractions was monitored to the apoB levels of starting VLDL  IDL and the
concentrations of Lp-B:C, Lp-B:C:E and Lp-A-II:B:C:by measuring absorption at 280 nm by a single path
monitor UV-1 optical unit (Pharmacia Fine Chemicals, D:E particles were expressed in terms of corresponding
apoB values (mg apoB/100 mg TG). The between assayPiscataway, NJ, USA) attached to a recorder. The non-
adsorbed proteins and lipoproteins (the unretained frac- coefficients of variations for anti-apoA-II R-fraction, anti-
apoC-III R-fraction and anti-apoE R-fraction were 9 totions) were eluted with the running buffer (0.05 mol/L
Tris-HCl buffer, pH 7.4, containing 0.15 M NaCl and 10%, 8 to 9% and 6 to 7%, respectively.
1.5 mg/mL EDTA). After the absorbance at 280 nm
Determination of lipids and apolipoproteinsreturned to the baseline, the apoB-containing lipopro-
teins bound to the immunosorber (the retained fractions) Plasma total cholesterol (TC; CHOP/PAP; Boehringer,
Mannheim, Germany) and TG (kits for total TG andwere desorbed and eluted with 4.5 mol/L sodium thio-
cyanate at a flow rate of 30 mL/h. The bottom layer of free glycerol; Abbott Laboratories, Diagnostic Division,
Irving, TX, USA) concentrations were determined en-Sephadex G-25 allowed an immediate separation of re-
tained lipoproteins from the desorbent, which resulted zymatically on an Abbott VP-Super System Analyzer.
High-density lipoprotein (HDL) cholesterol was mea-in two distinct peaks at 280 nm [27]; the first peak con-
sisted of adsorbed lipoproteins and the second peak con- sured by a modified heparin-manganese precipitation
procedure of Warnick and Albers [30]. These threetained sodium thiocyanate. The unretained (U) and re-
tained (R) fractions from each immunosorber were placed assays were standardized with plasma calibrators and
control samples supplied by the Centers for Disease Con-in dialysis bags (5000 molecular wt cut-off) and concen-
trated to 5 to 10 mL volumes by reverse dialysis against a trol, Atlanta, Georgia. VLDL-cholesterol levels were
assumed to equal one fifth of the plasma TG concentra-saturated aqueous solution of polyvinylpyrrolidone K30
(Acros Organics, Pittsburgh, PA, USA) placed outside tion, and low-density lipoprotein (LDL) cholesterol lev-
els were determined by the method of Friedewald, Levydialysis bags. Dialysis bags were rinsed with distilled water
and placed into solid sucrose to finish concentrating U- and Fredrickson [31]. Cholesterol esters (CE), free cho-
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Table 1. Concentrations of plasma lipids in uremic patients and lipoproteins) than controls, the difference in the levels
normal controls
of these apolipoproteins between patients and controls
Total cholesterol Triglycerides VLDL-C LDL-C HDL-C was greater in the CRF-II than CRF-I patient group.
Subjects N mmol/L ApoA-I levels were significantly lower in CRF-II, but
not CRF-I, in comparison with controls. There was noCRF-I 18 6.21.6a 2.21.2a 1.00.5a 4.41.3a 1.00.3
CRF-II 8 6.11.2a 1.90.3b 0.90.2b 4.41.2a 0.80.14a difference in the levels of apoC-III-HS (apoC-III bound
Controls 10 4.90.8 1.20.3 0.60.1 3.40.8 1.10.2 to apoA-I-containing lipoproteins) between patient and
Data are mean  SD. Abbreviations are: CRF-I, patients before dialysis; control subjects. The apoC-III-HS/apoC-III-HP ratio
CRF-II, patients on hemodialysis.
was higher in controls than patient groups, but the sig-CRF-I, CRF-II vs. Controls; a P  0.02 and b P  0.001
nificance level was only reached between controls and
CRF-II patients.
Kinetic properties of VLDL  IDLlesterol (FC) and TG in VLDL  IDL were determined
by GC according to a procedure by Kuksis et al [26]. To determine the contribution of compositional ab-
The quantitative determination of apolipoproteins normalities to the accumulation of TG-rich lipoproteins
was performed by previously described electroimmu- in patients with renal insufficiency, the lipolytic rate con-
noassay for apoA-I [32], apoB [29], apoC-III [33], and stants of VLDL  IDL fractions were determined in
apoE [34]. The measurement of apoC-III bound to apoA- CRF-I and CRF-II patients and compared with corre-
(HDL) and apoB- (VLDL  LDL) containing lipopro- sponding rate constants of asymptomatic control sub-
teins was performed on heparin-Mn supernates (apoC- jects. Results presented in Table 3 show no difference
III-HS) and heparin-Mn precipitate (apoC-III-HP), in the mean k1 values between patients at the earlier
respectively, according to a previously described proce- stages of renal dysfunction (CRF-I) and patients on he-
dure [35]. The apoC-III-ratio was calculated as apoC- modialysis (CRF-II). However, the k1 values of both
III-HS / apoC-III-HP. patient groups were significantly (P  0.0005 for CRF-I
and P  0.001 for CRF-II patients) lower than those of
Determination of glomerular filtration rate control subjects. The time course of TG lipolysis cata-
Glomerular filtration rate (GFR) was determined as lyzed in a standardized assay by bovine LPL showed
the plasma or renal clearance of 51Cr-EDTA [36]. The significant differences between patients and controls at
renal clearance method was used when the GFR value all time points (from 10 to 60 min; Fig. 1). These results
was below 20 mL/min/1.75 m2 BSA. suggest the existence of considerable abnormalities in
the composition and/or concentration of apolipoprotein-
Statistical analysis defined lipoprotein families in VLDL  IDL of patients
Conventional statistical methods were used to describe with renal insufficiency.
the salient features of the results. The Student unpaired
Composition of VLDL  IDLtwo-tailed t test was used to test the significance of differ-
ences between means. A difference between variables To identify the possible compositional abnormalities,
with P value0.05 was considered significant. The corre- the VLDL  IDL fractions from patients and controls
lation coefficients were calculated by Spearman’s rank were characterized by measurements of lipids, apolipo-
correlation method. proteins and apoB-containing lipoprotein families.
The determination of neutral lipid composition of
VLDL  IDL fractions revealed significant differencesRESULTS
in the percentage composition of TG, CE and FC be-
Plasma lipid and apolipoprotein profiles tween patients and controls (Table 4). The percentage
There were no significant differences in the levels of composition of neutral lipids of VLDL  IDL from
plasma lipids between CRF-I and CRF-II patients (Ta- CRF-I patients was very similar, if not identical, to that
ble 1). On the other hand, both patient groups had sig- of VLDL  IDL from CRF-II patients. However, when
nificantly higher concentrations of TC, TG, VLDL-C and compared to neutral lipids of controls, the relative con-
LDL-C than controls; however, only CRF-II patients had tent of TG was significantly lower and the relative con-
significantly lower levels of HDL-C than control subjects. tents of CE and FC were significantly higher in both
Except for significantly lower apoA-I levels (P  patient groups.
0.001), the apolipoprotein profile of CRF-II patients did Concentrations of apolipoproteins B, C-III and E (nor-
not differ from that of CRF-I patient group (Table 2). malized to 100 mg TG per VLDL  IDL fraction) dif-
Although both CRF-I and CRF-II patients had signifi- fered significantly between and, in some cases, within
cantly higher concentrations of apolipoproteins B, C-III, the patient groups and controls (Table 5). The CRF-I
patients had significantly lower levels of apoB (P 0.01)E and C-III-HP (apoC-III bound to apoB-containing
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Table 2. Concentrations of plasma apolipoproteins in uremic patients and normal controls
Apolipoproteins mg/dL
N A-I B C-III E C-III-HS C-III-HP C-III ratio
CRF-I 18 11622 12736c 19.48.9b 13.05.6a 5.22.0 11.57.3a 0.800.85
CRF-II 8 849.4b 13937c 22.93.9d 16.06.7b 7.33.8 13.43.3d 0.620.42a
Controls 10 12016 9114 11.62.8 9.74.5 4.50.8 4.71.5 0.950.30
Data are mean  SD. Abbreviations are in Table 1.
CRF-I, CRF-II vs. Controls: a P  0.05, b P  0.01, c P  0.001, d P  0.0005
Table 4. Neutral lipid composition of VLDL  IDL of uremicTable 3. Kinetic rate constants for lipolysis of VLDL  IDL of
uremic patients and normal controls patients and normal controls
Neutral lipids %Lipolytic rate constant
Subjects N k1 min1 P value Subjects N Triglycerides Cholesterol ester Free cholesterol
CRF-I 18 0.03410.0111 0.0005
CRF-I 18 60.45.5c 30.75.5c 8.91.2cCRF-II 8 0.03520.0076 0.001
CRF-II 8 59.76.3b 30.66.6a 9.71.9cControls 10 0.05150.0103
Controls 10 72.59.5 21.08.7 6.51.2
Data are mean  SD. Abbreviations are in Table 1. P values denote the sig-
Data are mean  SD. Abbreviations are in Table 1.nificance of difference when CRF-I and CRF-II are compared to normal controls.
CRF-1, CRF-II vs. Controls: a P  0.01, b P 0.005, c P  0.001
Table 5. Concentrations of apolipoproteins per 100 mg triglycerides
in VLDL  IDL of uremic patients and normal controls
Apolipoproteins mg/100 mg TG
Subjects N B C-III E C-III/B E/B
CRF-I 18 28.29.6c 6.32.3d 5.43.3 0.220.09 0.160.08a
CRF-II 8 44.018.8d 5.81.9b 9.89.6 0.170.08 0.210.14
Controls 10 18.95.1 3.81.5 4.93.2 0.220.11 0.260.19
Data are mean  SD. Abbreviations are the same as Table 1.
CRF-I, CRF-II vs. Controls: a P  0.05, b P  0.025, c P  0.005, d P 0.0005
Table 6. Concentrations of complex ApoB-containing lipoprotein
families per 100 mg triglycerides in VLDL  IDL of uremic
patients and normal controls
Lp-A-II:B:C:D:E Lp-B:C Lp-B:C:E
Subjects N mg/100 mg TG
CRF-I 18 4.63.7 9.87.8b 12.37.0
CRF-II 8 5.25.5 9.15.4c 17.90.8d
CRF-I II 26 4.74.1 9.67.1c 13.66.6a
Controls 10 3.61.7 2.71.5 8.44.5
Data are mean  SD. Abbreviations are in Table 1.
CRF-I, CRF-II, CRF-I  II vs. Controls: a P  0.05, b P  0.01, c P  0.005,
d P  0.001
Fig. 1. Time course of the lipolytic degradation of very-low density
lipoprotein (VLDL)  intermediate density lipoprotein (IDL) from
uremic patients and controls catalyzed by bovine milk lipoprotein lipase.
VLDL IDL fractions of patients on hemodialysis wereSymbols are: () predialytic patients (CRF-I); () patients on hemodi-
alysis (CRF-II); () controls. There was no significant difference be- enriched with apoB and apoE, but this increase had no
tween CRF-I and CRF-II at all time points, and there were no significant additional effect on the lipolytic rate.differences between controls and both CRF-I and CRF-II at all time
Due to significant increases of apoB and apoC-III con-points except at five minutes.
centrations of VLDL  IDL fractions from uremic pa-
tients, it was of considerable interest to determine the
levels of individual TG-rich lipoprotein families, all ofand apoE (P  0.05) than CRF-II patients. However,
both patient groups had significantly higher concentra- which are characterized by apolipoproteins B and C-III
as main protein constituents. As shown in Table 6, thetions of apoB and apoC-III, but not apoE, than normal
controls. In comparison with predialytic patients, the levels of Lp-A-II:B:C:D:E, Lp-B:C, and Lp-B:C:E parti-
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Table 7. Correlations between lipolytic rate constant, k1, and expressed both in terms of the percent content (r 
neutral lipids and Lp-A-II:B:C:D:E particles in VLDL  IDL
0.47) and concentration (r  0.46) of Lp-A-II:B:of uremic patients
C:D:E particles.
Patients N Correlation variables r Coefficients P value In contrast to uremic patients, there was no correlation
CRF-I II 26 Free cholesterol % 0.81 0.001 between plasma or VLDL IDL lipids, apolipoproteins
CRF-I II 26 Esterified cholesterol % 0.63 0.001
and lipoprotein families and k1 values in control subjects.CRF-I II 26 Triglycerides % 0.72 0.001
CRF-I II 26 Lp-A-II:B:C:D:E % 0.47 0.03 The lipolytic rate constant was not correlated with
CRF-I II 26 Lp-A-II:B:C:D:E mg/100 mg TG 0.46 0.03 GFR in CRF-I patients.
Abbreviations are in Table 1.
DISCUSSION
The results of present study have provided additional
cles, normalized to 100 mg TG of VLDL IDL fractions, evidence that the characteristic accumulation in renal
were determined in both patient groups and compared insufficiency of intact and/or partially metabolized TG-
separately and as a combined patient population with rich apoB-containing lipoproteins is related to a defect(s)
those of normal subjects. Numerically, the levels of in the lipolytic degradation of these lipoproteins. The
Lp-A-II:B:C:D:E particles were higher in all three pa- retarded catabolism of TG-rich VLDL and IDL has been
tient groups than controls. The concentration of Lp-B:C generally attributed to the reduced enzymic activity of
particles was significantly higher in CRF-I (P  0.01) LPL [7, 8, 10–13]. However, it has been reported more
and CRF-II (P  0.005) patients and in the combined recently that a low LPL activity may not be the only
patient group (P  0.005) in comparison with control factor responsible for impaired degradation of TG-rich
subjects. The Lp-B:C:E particle levels of uremic patients lipoproteins [14–16]. Arnadottir et al have shown that,
were also higher than those of normal controls, but the due to abnormal lipid and apolipoprotein composition,
statistical significance was only reached in patients on VLDL isolated from patients on hemodialysis is a poor
hemodialysis (P  0.001) and in the combined patient substrate for bovine LPL.
population (P 0.05). These results indicate that in both To further explore the possible underlying defect(s)
patient groups, the accumulation of TG-rich lipoproteins responsible for the slow lipolysis of TG-rich lipoproteins,
in VLDL  IDL fraction is due to a 3.5-fold increase the present study has been extended to renal patients
in the levels of Lp-B:C particles accompanied by smaller with a wider spectrum of renal dysfunction by including
increases in the levels of Lp-A-II:B:C:D:E and Lp-B:C:E patients before dialysis as well as patients on hemodialysis.
particles. Since the intact and partially delipidized TG-rich lipo-
proteins accumulate in both VLDL and IDL density re-
Correlations between lipolytic rate constant gions [6, 37, 38], these two lipoprotein density fractions
and lipoproteins were combined and characterized by the determination
Since there was no difference in the mean values of of lipolytic rate constant (k1) and lipid, apolipoprotein
the lipolytic rate constant (k1) between the CRF-I and and apoB-containing lipoprotein particle profiles.
CRF-II patient groups (Table 3), these two groups were In contrast to a previously reported study by Arnadot-
combined to determine any possible correlations be- tir et al [15] using a fluorescent phospholipid analog to
tween the k1 values and lipids, apolipoproteins and lipo- determine the lipolytic kinetics of VLDL from hemodial-
protein families of VLDL  IDL fractions. There were ysis patients, we have determined the lipolytic rates by
no significant correlations between the k1 values and any measuring the actual TG mass remaining after lipolysis
of the plasma lipids and apolipoproteins. However, all of VLDL  IDL fractions. Whereas the former study
three neutral lipid constituents of VLDL  IDL corre- [15] showed a difference in the extent of lipolysis, but not
lated significantly with k1 values (P 0.001); the relative in the initial rate of lipolysis between VLDL from pa-
contents of FC (r  0.81) and CE (r  0.63) corre- tients and controls, the direct measurement of TG in the
lated negatively, while the percent content of TG corre- present study showed that both the initial rate and extent
lated positively (r 0.72) with the lipolytic rate constant of lipolysis were significantly different between VLDL
(Table 7). In contrast, none of the measured apolipopro- IDL substrates from patients and controls. These differ-
teins of VLDL  IDL correlated significantly with the ences in kinetic findings were due most probably to dif-
k1 values. ferent methodologies used in these two studies.
Among the three major TG-rich lipoprotein families The lipolytic rates of VLDL IDL fractions from pa-
of VLDL  IDL fraction neither Lp-B:C nor Lp-B:C:E tients before dialysis and patients on hemodialysis were
correlated with the k1 values. However, there was a sig- significantly lower than those from asymptomatic con-
nificant (P  0.03) negative correlation between the trols, indicating that TG-rich lipoproteins of very low and
intermediate density properties from both patient groupslipolytic rate constant and Lp-A-II:B:C:D:E particles
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are a poor substrate for bovine milk LPL, and that this 54.1%). Furthermore, the mean values of neutral lipid
composition of Lp-A-II:B:C:D:E particles (CE 40.3%,metabolic defect is already present at the earlier stages
of renal insufficiency. The possibility that the decreased FC  8.1%, TG  52.5%, N  8) and Lp-B:C  Lp-B:
C:E particles (CE  35.2%, FC  7.5%, TG  57.2%,lipolytic rate was due to increased plasma triglyceride
levels was ruled out, because the k1 values of VLDL  N 8) from renal patients were found to be significantly
(P  0.0001 for CE and TG, but NS for FC) differentIDL fractions from asymptomatic subjects with mild hy-
pertriglyceridemia were within the normal range (data from those of corresponding Lp-A-II:B:C:D:E particles
(CE  20.7%, FC  7.2%, TG  72.0%, N  6) andnot shown). Both patient groups had abnormal plasma
lipid and apolipoprotein levels in comparison with nor- Lp-B:C Lp-B:C:E particles (CE 12.5%, FC 6.9%,
TG  80.6%, N  6) from control subjects. Taken to-mal controls. The only significant differences between
the CRF-I and CRF-II patients were in the levels of gether, these findings suggest that the levels of Lp-A-
II:B:C:D:E particles and the abnormal neutral lipid com-plasma apoA-I (P  0.001) and apoC-III-HS (P  0.05;
Table 2). However, since these two patient groups had position of all TG-rich lipoprotein particles represent
the main factors affecting the lipolytic rates of VLDL similar k1 values, the apoA-I-containing lipoproteins were
ruled out as a significant factor affecting the lipolytic rates. IDL fractions in patients with renal insufficiency. This
is, to our knowledge, the first indication that a specificThe lipid and apolipoprotein composition of VLDL
IDL fractions characterized by high percent contents of apolipoprotein-defined lipoprotein family within a het-
erogeneous lipoprotein density class is closely associatedFC and CE, relatively low percentage of TG and in-
creased levels of apolipoproteins B and C-III suggested with a defective metabolic process in renal disease.
Arnadottir et al found a significant inverse correlationthat the reduced lipolytic rates of TG-rich lipoproteins
in both CRF-I and CRF-II patients may be related to between the extent of lipolysis and increased levels of
apoC-III bound to apoB-containing lipoproteins [15].increased concentrations of apoC-III- and apoB-con-
taining lipoprotein families of abnormal neutral lipid In contrast, results of this study showed no significant
correlation between the lipolytic rate constant, k1, and thecomposition. To test this possibility, it was necessary to
determine the potential effect of three major TG-rich increased levels of apoC-III bound to apoB-containing
lipoproteins. However, there was a significant inverselipoprotein families, that is, Lp-B:C, Lp-B:C:E and Lp-A-
II:B:C:D:E, on the lipolytic rate constants of VLDL  correlation between the k1 values and the levels of Lp-A-
II:B:C:D:E particles, as one of the apoC-III-containingIDL from renal patients and control subjects. In all pa-
tients, there was a significant increase in the levels of TG-rich lipoproteins. These differences were due most
probably to differences in kinetic parameters, substrates,Lp-B:C and Lp-B:C:E and a numerical increase in the
concentration of Lp-A-II:B:C:D:E particles. However, and selection of patients. However, the results of both
studies suggested a possible association of apoC-III withboth the relative and absolute contents of Lp-A-II:B:
C:D:E particles showed a statistically significant negative impaired catabolism of some of the TG-rich lipoproteins.
There are several reports in the literature indicatingcorrelation (Table 7) with the lipolytic rate constant of
VLDL  IDL fractions, indicating that even a slight the occurrence of LPL inhibitors in uremic plasma at
density higher than 1.25 g/mL [6, 16]. However, since inincrease in the levels of this complex lipoprotein family
had a significant effect on the lipolytic degradation of this study VLDL  IDL were isolated ultracentrifugally
at a density less than 1.019 g/mL, the possible presenceTG-rich lipoproteins. Moreover, the significant inverse
correlation between the lipolytic rate and percent con- of inhibitors can be ruled out.
By measuring oxidative stress in VLDL  IDL of pa-tents of FC and CE of VLDL  IDL on one hand and
a positive correlation with that of TG (Table 7) on the tients and controls using a newly developed procedure
[39], it was shown that the lipolytic rate constant, k1, wasother showed clearly that neutral lipid composition of
substrate is also a significant factor affecting the lipolytic not correlated with the oxidative indexes (r  0.18, P 
0.33 for oxidative index 1 and r  0.13, P  0.48 for oxi-rates: the higher the relative contents of FC and CE and
the lower the relative content of TG, the lower the k1 dative index 2); this finding ruled out the possible contri-
bution of oxidized lipids to reduced k1-values. Similarly,values and vice versa. It has been previously established
that Lp-A-II:B:C:D:E particles isolated from VLDL of the measurement of five molecular species of TG sepa-
rated by GC on the basis of the fatty acid chain lengthspatients with Tangier disease or type V hyperlipopro-
teinemia have k1 values significantly lower than those of showed no significant difference in the composition of TG
molecular species between patients and controls; basedLp-B:C and Lp-B:C:E particles [21]. However, the Lp-A-
II:B:C:D:E, Lp-B:C and Lp-B:C:E particles from Tangier on this finding, a possible contribution of fatty acids to
reduced k1 values has been ruled out.or type V hyperlipoproteinemic subjects had normal
neutral lipid composition (CE  14.5%, FC  6.8%, The lack of a significant correlation between k1 and
GFR values suggests that the reduced lipolytic rate ofTG  78.6%) in comparison with that of VLDL  IDL
from renal patients (CE  37.5%, FC  8.3%, TG  VLDL  IDL fractions may not be associated with the
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degree of renal functional impairment. It appears that rotic lesions. Results of the Monitored Atherosclerosis
once the renal dysfunction has resulted in abnormal com- Regression Study (MARS) have indicated that the pro-
position and concentration of TG-rich lipoproteins, oc- gression of coronary artery disease in non-renal sub-
curring already at the early stages of renal insufficiency jects is significantly associated with increased levels of
[40], the reduced lipolytic rate will not be affected by directly measured Lp-Bc and Lp-A-II:B:C:D:E particles
further changes in renal function. [48]. More recently, apoC-III bound to apoB-containing
One can only speculate about the sequence of events lipoproteins was found to be an independent predictor
leading to the abnormal neutral lipid composition of TG- of recurrent coronary events in the Cholesterol and Re-
rich lipoprotein families and increased levels of Lp-A- current Events (CARE) Trial [49]. In contrast to Lp-B:
II:B:C:D:E particles as the most probable factors con- C:E, the Lp-B:C particles seem to have a very low bind-
tributing to decreased lipolytic rates of VLDL  IDL ing affinity for the LDL receptors [50, 51] and, thus, may
fractions in renal insufficiency. This chain of events may have longer residence time in the systemic circulation
be initiated by a reduced plasma lipolytic activity shown than apoE-containing Lp-B:C:E or Lp-A-II:B:C:D:E par-
to occur already at the early stages of renal insufficiency ticles. It has already been shown in a preliminary study
[10, 41]. Consequently, a partial hydrolysis of TG would that Lp-B:C particles are taken up by human THP1 mac-
result in a changed neutral lipid composition of TG-rich rophage at a higher rate than other apoB-containing
lipoproteins characterized by increased contents of FC lipoprotein families; macrophages incubated with Lp-B:C
and CE and decreased content of TG [14, 15, 38, 42–44]. were readily transformed into foam cells suggesting a
The increased cholesterol ester transfer from HDL to marked atherogenic potential of these lipoprotein par-
VLDL and IDL, at least in patients with microalbumin- ticles (abstract; Koren et al, Atherosclerosis 109:217, 1994).
uria or proteinuria [45], and/or the proposed hepatic However, it still remains to be established to what extent
formation of cholesterol-rich VLDL [43] may represent individual TG-rich lipoprotein particles also may contrib-
the other sources of cholesterol-enriched VLDL and ute to the accelerated atherosclerosis in patients with CRF.
IDL in renal insufficiency. The reduced lipolytic activ- In conclusion, results of this study have provided addi-
ity and decreased substrate affinity for LPL (due to in- tional evidence that the accumulation in renal insuffi-
creased cholesterol/triglyceride ratio of substrate) would ciency of intact and/or partially delipidized TG-rich apoB-
then result in the accumulation of partially delipidized containing lipoproteins is related, at least in part, to a
Lp-B:C, Lp-B:C:E and Lp-A-II:B:C:D:E particles as lipo- defect in the lipolytic degradation of these lipoproteins.
protein family constituents of VLDL  IDL fractions. The lipolytic rate constant, k1, of combined VLDL and
Due to their inherently low affinity for LPL, any in- IDL fractions from patients with chronic renal failure
creases in the levels of Lp-A-II:B:C:D:E particles would before dialysis and patients on hemodialysis was signifi-
further contribute to the low k1-values of VLDL  IDL cantly lower than that of asymptomatic control subjects.
fractions. The levels of all three major apolipoprotein-defined
Although the reduced lipolytic rate of VLDL  IDL Lp-B:C, Lp-B:C:E and Lp-A-II:B:C:D:E particles occur-
fractions does not seem to be associated with the de- ring in VLDL  IDL fractions were increased in renal
gree of renal dysfunction, the accumulation of modified patients in comparison with controls and had an abnor-
Lp-B:C, Lp-B:C:E and Lp-A-II:B:C:D:E particles may mal neutral lipid composition characterized by increased
play a significant pathophysiologic role in renal disease. relative contents of free and esterified cholesterol and
We have shown recently in a prospective study [46] that decreased percentage of triglycerides. Correlation analy-
the rate of progression of human chronic renal insuffi- ses have shown that increased levels of Lp-A-II:B:C:D:E
ciency was significantly associated with the sum of triglyc- particles and the abnormal neutral lipid composition of
eride-rich Lp-B:C, Lp-B:C:E and Lp-A-II:B:C:D:E parti- all TG-rich lipoproteins represent the main factors af-
cles (Lp-Bcomplex) of very low and intermediate densities, fecting the in vitro lipolytic rates of VLDL  IDL frac-
but not with cholesterol-rich Lp-B particles, the main tions in patients with renal insufficiency. Whether these
lipoprotein species of LDL. This finding has been re- factors also affect lipolytic processes in vivo remains to
cently supported by results of the prospective Athero- be established in future studies.
sclerosis Risk in Community Study (ARIC) showing that
high TG and low HDL-C, but not LDL-C, predict an ACKNOWLEDGMENTS
increased risk of renal dysfunction [47]. It still remains to
This study was supported by the Swedish Medical Research Councilbe determined, however, whether there are differences
(B93-19X-10406-01A); Riksfo¨rbundet fo¨r Njursjuka, Sweden; Njurs-
among the three major TG-rich lipoprotein families in juka Fo¨rening i Va¨stverige, Sweden; the Brit Wennerstro¨m Research
Foundation, Go¨teborg, Sweden; the Salhgrenska University Hospital,the degree of kidney damage.
the University of Go¨teborg, Go¨teborg, Sweden; and the resources ofThe TG-rich lipoprotein families may not only contrib-
the Oklahoma Medical Research Foundation, Oklahoma City, Okla-
ute to the progression of renal dysfunction but also play homa, USA. The authors gratefully acknowledge the colleagues and
staff of the following renal units participating in the study for theira role in the development and progression of atheroscle-
Lee et al: Lipoprotein and lipolysis in CRF 217
contributions: Department of Nephrology, Karlstad Hospital, Karlstad, 16. Arnadottir M: Pathogenesis of dyslioprotinemia in renal insuffi-
ciency: The role of lipoprotein lipase and hepatic lipase. Scand JSweden; Department of Nephrology, Sahlgrenska University Hospital,
University of Go¨teborg, Go¨teborg, Sweden. We also gratefully ac- Clin Lab Invest 57:1–11, 1997
17. Ewing AM, Freeman NK, Lindgren FT: The analysis of humanknowledge the staff of the Lipid and Lipoprotein Laboratory, Okla-
homa Medical Research Foundation, Oklahoma City Oklahoma, USA, serum lipoprotein distribution. Adv Lipid Res 3:25–61, 1965
18. Nestel P, Billington T, Tada N, et al: Heterogeneity of very-for their skillful handling of the lipoprotein analyses.
low-density lipoprotein metabolism in hyperlipidemic subjects.
Metabolism 32:810–817, 1983Reprint requests to Diana M. Lee, Ph.D., Lipid and Lipoprotein
Laboratory, Oklahoma Medical Research Foundation, 800 Research 19. Demant T, Shepherd J, Packard CJ: Very low density lipoprotein
apolipoprotein B metabolism in humans. Klin Wochenschr 66:703–Parkway, Suite 340, Oklahoma City, Oklahoma 73104, USA.
E-mail: Diane-Lee@omrf.ouhsc.edu. 712, 1988
20. Alaupovic P: Apolipoprotein composition as the basis for classify-
ing plasma lipoproteins. Characterization of ApoA- and ApoB-
containing lipoprotein families. Prog Lipid Res 30:105–138, 1991APPENDIX
21. Alaupovic P, Knight-Gibson C, Wang C-S, et al: Isolation and
characterization of an apoA-II-containing lipoprotein (Lp-A-II:BAbbreviations used in this article are: apo, apolipoprotein; CE,
cholesterol esters; CRF, chronic renal failure; FC, free cholesterol; complex) from plasma very low density lipoproteins of patients
with Tangier disease and type V hyperlipoproteinemia. J LipidGC, gas chromatography; HDL, high density lipoproteins; HP, heparin-
manganese precipitate; HS, heparin-manganese supernate; IDL, inter- Res 32:9–19, 1991
22. Lee DM: Apolipoprotein B-48: problems related to quantification.mediate density lipoproteins; LDL, low density lipoproteins; Lp-B:C,
lipoprotein B:C; Lp-B:C:E, lipoprotein B:C:E; Lp-A-II:B:C:D:E, lipo- Methods Enzymol 263:146–165, 1996
23. Lee DM, Downs D: A quick and large-scale density gradientprotein A-II:B:C:D:E; LPL, lipoprotein lipase; TC, total cholesterol;
TG, triglycerides; VLDL, very low density lipoproteins. subfractionation method for low density lipoproteins. J Lipid Res
23:14–27, 1982
24. Posner I, Wang C-S, McConathy WJ: The comparative kinetics
REFERENCES of soluble and heparin Sepharose-immobilized bovine lipoprotein
lipase. Arch Biochem Biophys 226:306–316, 19831. Bagdade JD, Porte D, Bierman EL: Hypertriglyceridemia: a met-
25. McConathy WJ, Gesquiere JC, Bass H, et al: Inhibition of lipopro-abolic consequence of chronic renal failure. N Engl J Med 279:181–
tein lipase activity by synthetic peptides of apolipoprotein-C-III.185, 1968
J Lipid Res 33:995–1003, 19922. Bagdade JD, Albers JJ: Plasma high-density lipoprotein concen-
26. Kuksis A, Myher JJ, Marai L, Geher K: Determination of plasmatration in chronic-hemodialysis and renal transplant patients. N
lipid profiles by automated gas chromatography and computerizedEngl J Med 296:1436–1439, 1977
data analysis. J Chromatogr Sci 13:423–430, 19813. Nestel PJ, Fidge NH, Tan MH: Increased lipoprotein remnant
27. Dashti N, Alaupovic P, Knight-Gibson C, Koren E: Identifica-formation in chronic renal failure. N Engl J Med 307:329–333, 1982
tion and partial characterization of discrete apolipoprotein B-con-4. Ron D, Oren I, Aviram M, et al: Accumulation of lipoprotein
taining lipoprotein particles produced by human hepatoma cellremnants in patients with chronic renal failure. Atherosclerosis 46:
line HepG2. Biochemistry 26:4837–4846, 198767–75, 1983
28. Alaupovic P, Hodis HN, Knight-Gibson C, et al: Effects of lovas-5. Attman PO, Alaupovic P, Gustafson A: Serum apolipoprotein
tatin on apoA- and apoB-containing lipoprotein families in a sub-profile of patients with chronic renal failure. Kidney Int 32:368–
population of patients participating in the Monitored Atheroscle-375, 1987
rosis Regression Study (MARS). Arterioscler Thromb 14:1906–6. Attman P-O, Samuelsson O, Alaupovic P: Lipoprotein metabo-
1914, 1994lism and renal failure. Am J Kidney Dis 21:573–592, 1993
29. Curry MD, Gustafson A, Alaupovic P, McConathy WJ: Elec-7. Applebaum-Bowden D, Goldberg AP, Hazzard WR, et al: Post-
troimmunoassay, radioimmunoassay, and radial immunodiffusionheparin plasma triglyceride lipase in chronic hemodialysis: Evi-
assay evaluated for quantification of human apolipoprotein B. Clindence for a role for hepatic lipase in lipoprotein metabolism.
Chem 24:280–286, 1978Metabolism 28:917–924, 1979
30. Warnick GR, Albers JJ: A comprehensive evaluation of the hepa-8. Savdie E, Gibson JC, Crawford GA, et al: Impaired plasma tri-
rin-manganese precipitation procedure for estimating high densityglyceride clearance as a feature of both uremic and posttransplant
lipoprotein cholesterol. J Lipid Res 19:65–76, 1978triglyceridemia. Kidney Int 18:774–782, 1980
31. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the9. Chan MK, Varghese Z, Persaud JW, et al: Hyperlipidemia in
concentration of low-density lipoprotein cholesterol in plasma,patients on maintenance hemo- and peritoneal dialysis: the relative
without use of the preparative ultracentrifuge. Clin Chem 18:499–pathogenetic roles of triglyceride production and triglyceride re-
502, 1972moval. Clin Nephrol 17:183–190, 1982
32. Fesmire JD, McConathy WJ, Alaupovic P: Use and significance10. McCosh EJ, Solangi K, Rivers JM, Goodman A: Hypertriglyceri-
of reference serum as a secondary standard for electroimmunoas-demia in patients with chronic renal insufficiency. Am J Clin Nutr
say of apolipoprotein A-I. Clin Chem 30:712–716, 198428:1036–1043, 1975
33. Curry MD, McConathy WJ, Fesmire JD, Alaupovic P: Quantita-11. Ibels LS, Reardon MF, Nestel PJ: Plasma post-heparin lipolytic
tive determination of human apolipoprotein C–III by electroimmu-activity and triglyceride clearance in uremic and hemodialysis
noassay. Biochim Biophys Acta 617:505–513, 1980patients and renal allograft recipients. J Lab Clin Med 87:648–
34. Curry MD, McConathy WJ, Alaupovic P, et al: Determination of658, 1976
human apolipoprotein E by electroimmunoassay. Biochim Biophys12. Chan MK, Persaud J, Varghese Z, Moorhead JF: Pathogenetic
Acta 439:413–425, 1976roles of post-heparin lipases in lipid abnormalities of hemodialysis
35. Attman P-O, Alaupovic P: Lipid and apolipoprotein profiles ofpatients. Kidney Int 25:812–818, 1984
uremic dyslipoproteinemia—relation to renal function and dialysis.13. Mordasini R, Frey F, Flury W, et al: Selective deficiency of hepatic
Nephron 57:401–410, 1991triglyceride lipase in uremic patients. N Engl J Med 297:1362–1366,
36. Jagenburg R, Attman P-O, Aurell M, Bucht H: Determination1977
of glomerular filtration rate in advanced renal insufficiency. Scand14. Arnadottir M, Thysell H, Dallongeville J, et al: Evidence that
J Urol Nephrol 12:133–137, 1978reduced lipoprotein lipase activity is not a primary pathogenetic
37. Attman P-O, Tavella M, Knight-Gibson C, et al: Apolipoproteinfactor for hypertriglyceridemia. Kidney Int 48:779–784, 1995
B-containing lipoprotein particles in progressive renal insuffi-15. Arnadottir M, Dallongeville J, Fruchart J-C, Nilsson-Ehle
ciency. Contrib Nephrol 98:11–19, 1992P: Very-low-density lipoprotein of uremic patients is a poor sub-
38. Attman P-O, Alaupovic P, Tavella M, Knight-Gibson C: Abnor-strate for bovine lipoprotein lipase in vitro. Metabolism 45:686–
690, 1996 mal lipid and apolipoprotein composition of major lipoprotein
Lee et al: Lipoprotein and lipolysis in CRF218
density classes in patients with chronic renal failure. Nephrol Dial apolipoprotein B-containing lipoprotein particles are associated
with a higher rate of progression of human chronic renal insuffi-Transplant 11:63–69, 1996
39. Lee DM: A simple and sensitive method in using the ratios of ciency. J Am Soc Nephrol 9:1482–1488, 1998
47. Muntner P, Coresh J, Smith JC, et al: Plasma lipids and risk ofcholesteryl ester molecular species as indexes of oxidative stress in
plasma and lipoprotein fractions. Atherosclerosis 146:221–235, 1999 developing renal dysfunction: The Atherosclerosis Risk in Com-
munities Study. Kidney Int 58:293–301, 200040. Samuelsson O, Attman P-O, Knight-Gibson C, et al: Lipoprotein
abnormalities without hyperlipidaemia in moderate renal insuffi- 48. Alaupovic P, Mack WJ, Knight-Gibson, Hodis HN: The role of
triglyceride-rich lipoprotein families in the progression of athero-ciency. Nephrol Dial Transplant 9:1580–1585, 1994
41. Crawford GA, Savdie E, Steward JH: Heparin-released plasma sclerotic lesions as determined by sequential coronary angiography
from a controlled clinical trial. Arterioscler Thromb Vasc Biol 17:lipases in chronic renal failure and after renal transplantation. Clin
Sci 57:155–165, 1979 715–722, 1997
49. Sacks FM, Alaupovic P, Moye LA, et al: VLDL, apolipoproteins42. Norbeck HE, Carlson LA: Increased frequency of late pre-
lipoproteins (Lp) in isolated serum very low density lipoproteins B, CIII, and E, and risk of recurrent coronary events in the Choles-
terol and Recurrent Events (CARE) Trial. Circulation 102:1886–in uraemia. Eur J Clin Invest 10:423–426, 1980
43. Norbeck HE, Ro¨ssner S: Intravenous fat tolerance test with Intra- 1892, 2000
50. Agnani G, Bard JM, Candelier L, et al: Interaction of LpB,lipid in chronic renal failure. Acta Med Scand 211:69–74, 1982
44. Joven J, Villela E, Ahmad S, et al: Lipoprotein heterogeneity in LpB:E, LpB:C–III, and LpB:C–III:E lipoproteins with the low
density lipoprotein receptor of HeLa cells. Arterioscler Thrombend-stage renal disease. Kidney Int 43:410–418, 1993
45. Dullaart RPF, Gansevoort RT, Dikkeschei BD, et al: Role of 11:1021–1029, 1991
51. Clavey V, Lestavel-Delattre S, Copin C, et al: Modulation ofelevated lecithin-cholesterol acyltransferase and cholesterol ester
transfer protein activities in abnormal lipoproteins from protein- lipoprotein B binding to the LDL receptor by exogenous lipids
and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromburic patients. Kidney Int 44:91–97, 1993
46. Samuelsson O, Attman P-O, Knight-Gibson C, et al: Complex Vasc Biol 15:963–971, 1995
